Insights into the management of chronic hepatitis C in primary care using MedicineInsight CHRONIC HEPATITIS C (CHC) was previously a condition primarily managed by specialists. However, the listing of directacting antiviral (DAA) regimens on the Pharmaceutical Benefits Scheme (PBS), expanded prescriber eligibility and the release of Australian recommendations for the management of hepatitis C virus (HCV) infection in 2016 1 have expanded the role of general practitioners (GPs) in the management of patients with CHC. The shift to primary care of uncomplicated non-cirrhotic CHC aims to improve overall treatment access and uptake. 2 The latest estimates indicate there were 199,412 people living with CHC in Australia at the end of 2016. 2 Between March 2016 and June 2017, 43,360 patients started DAA treatment. 3 However, treatment initiation rates have more than halved, from 3000-5000 patients per month in the first six months following PBS listing to 1500-2000 patients per month as at June 2017. 3 Patients still living with CHC are likely to be at varying stages in the diagnosis and care continuum, and may require further assessment in order to be ready for treatment. Appendix A outlines pretreatment assessment for patients with HCV infection.
The aim of this study was to assess where patients with CHC are situated in the diagnosis and care continuum, highlight opportunities to improve pretreatment assessment and thereby increase overall DAA treatment uptake.
Method
A cross-sectional observational study was conducted using MedicineInsight, a national general practice data program developed and managed by NPS MedicineWise, with funding support from the Australian Government Department of Health. MedicineInsight is the first large-scale national general practice data program in Australia to extract and collate longitudinal, de-identified patient health records from clinical information systems (Best Practice, Medical Director 3 and Genie). 4 The MedicineInsight program collects de-identified data on patient demographics, encounters (not including progress notes), diagnoses, prescriptions, pathology tests and referrals, and includes records for about 3.6 million regular patients (approximately 15% of the Australian population) from more than 3300 GPs in 653 general practices across Australia.
This study was approved by Bellberry Human Research Ethics Committee (application number: 2016-11-792, approved 27 April 2017).
Participants
Patients with a diagnosis of HCV infection in their medical record were identified from general practices enrolled in the MedicineInsight program. For the purpose of this study, we included patients aged 18 years or older who had attended their general practice at least three times between 1 January 2013 and 31 August 2017, and who had a new hepatitis C-related entry recorded in this period. Appendix B and Table B1 (available online only) outline how patients with HCV infection were identified using MedicineInsight.
Patients were classified into two groups on the basis of the available information for their infection status: either 'indeterminate' (meaning their precise hepatitis status could not be Kendal Chidwick, Debra Kiss, Rachel Gray, Jeannie Yoo, Michael Aufgang, Amany Zekry Background and objectives Direct-acting antivirals (DAAs) became available for patients with chronic hepatitis C (CHC) in primary care in March 2016, yet not all patients will have undergone pre-treatment assessment. The aim of this study was to assess where patients with CHC are situated in the diagnosis and care continuum, to encourage general practitioners (GPs) to improve pretreatment assessment and increase DAA treatment uptake.
Method
This was a cross-sectional study of 4025 adult patients with CHC first recorded between 2013 and 2017, using the general practice data program MedicineInsight.
Results
Only half of all patients with confirmed CHC had a hepatitis C virus qualitative RNA recorded, and few patients had all recommended pretreatment assessments. The majority had low aspartate aminotransferase to platelet ratio index (APRI) scores.
Discussion
Incomplete pretreatment assessment is likely to be a reflection of the recent shift in management of CHC to primary care. The majority of patients have APRI results that suggest cirrhosis is unlikely, and they are potentially suitable for treatment in primary care. This highlights a substantial opportunity for GPs to recall patients for further assessment and treatment.
determined from the information available) or 'confirmed CHC'. Additional criteria were applied to patients initially classified as 'indeterminate' to further improve allocation of patients ( Figure 1 ). Patients whose records showed they no longer had HCV, either through treatment or spontaneous viral clearance, were excluded from the study.
Study outcomes
The main outcome is the number of patients who had undergone pretreatment assessment and management as recommended by current Australian guidelines 1 (Appendix A).
Statistics
Descriptive statistics were used to present the study outcomes, including use of percentages and associated 95% confidence intervals (CI), and means and standard deviations (SDs). Robust standard errors were used in the calculation of 95% CIs to adjust for clustering by practice. Data management and analyses were conducted with SAS Enterprise Guide 7.1 (Cary, NC USA, 2015).
Results
Of the 2.63 million patients in MedicineInsight practices who were aged ≥18 years with at least three practice visits between 1 January 2013 and 31 August 2017, 4025 patients were classified as having confirmed CHC during the study period, while 3137 patients were classified as having indeterminate hepatitis C infection ( Figure 1 ).
Patient characteristics
Approximately two-thirds of adult patients diagnosed with confirmed CHC during the study period were male (64.2%, 95% CI: 61.9, 66.5), with a mean age of 49 years (SD 12), and more than half were residents of a major city (59.0%, 95% CI: 51.0, 66.9; Table 1 ). Furthermore, 8.7% (95% CI: 6.6, 10.7) of patients with confirmed CHC identified as Aboriginal and/or Torres Strait Islander.
Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection was recorded for 2.7% (95% CI: 0.6, 4.8) and 2.5% (95% CI: 1.9, 3.1) of patients, respectively. Additionally, 9.2% (95% CI: 8.1, 10.4) of patients had a record of liver cirrhosis and 1.5% (95% CI: 1.1, 1.9) had a record of hepatocellular cancer.
Diagnosis of suspected chronic hepatitis C
Following a positive HCV antibody test, an HCV polymerase chain reaction (PCR) test is essential to confirm current hepatitis C infection. 1 In Patients with at least three visits between 1 January 2013 and 31 August 2017 AND ≥18 years of age n = 2,633,368 †Additional criteria applied to patients with indeterminate hepatitis C
The patient must have any of the following:
• a recorded onset date for hepatitis C more than 6 months before the most recent record
• another diagnosis recorded for hepatitis C in the 6 months to 3 years before the most recent record
• a prescription for a hepatitis C medicine
• a hepatitis C complication (cirrhosis, hepatocellular carcinoma)
• a liver investigation (ARFI, FibroScan, shear wave)
• an HCV viral load or HCV genotype test. Figure 2B ). Figure 2C ). Only 10 patients (0.3%, 95% CI: 0.0, 0.5) had all recommended baseline tests (HCV viral load, HCV genotype plus all the tests in Figure 2B and 2C) recorded during this time.
Other investigations

Liver fibrosis assessment
Overall, among the confirmed CHC group, our assessment showed that 56% (95% CI: 52.5, 59.3) had a calculated aspartate aminotransferase (AST) to platelet ratio index (APRI) score ≤1, indicating low probability of cirrhosis ( Figure 2D ). 1 Excluding patients in whom an APRI score was not assessable (eg AST and/or platelet test result were unavailable in the past two years), 84.6% of patients had an APRI score ≤1.
Only 35 patients (0.9%, 95% CI: 0.0, 1.7) had a record of a FibroScan (Echosens, Paris), shear wave elastography or acoustic radiation force impulse (ARFI) imaging in data fields collected by MedicineInsight (Figure 2E ).
Treatment and referral data
Treatment
Of the 4025 patients with confirmed CHC, 27.4% (1102 patients, 95% CI: 24.4, 30.3) had a record of any medicine for CHC, and 26.2% (1054 patients, 95% CI: 23.2, 29.2) had treatment with an interferonfree DAA regimen ( Figure 3A) . For a list of medicines included in this study, see Appendix C (available online only).
Specialist referral
MedineInsight data indicate that 9.6% (385 patients, 95% CI: 7.5, 11.6) of patients with confirmed CHC had a referral to a gastroenterologist, and 1.9% (76 patients, 95% CI: 0.9, 2.8) had a referral to an infectious diseases physician ( Figure 3B ) recorded in the 12 months after diagnosis. A further 41.9% of patients had a referral recorded, but the specialist type could not be ascertained from data collected by MedicineInsight. suggest a low likelihood of cirrhosis. Data released by the Kirby Institute also suggest that the majority of patients with CHC yet to be treated are those without cirrhosis. 3 Over a quarter (26.2%) of patients in the confirmed CHC group had been prescribed an interferon-free DAA regimen. As more than 90% of patients completing DAA therapy are expected to be cured of CHC, most of these patients will be those who are either yet to finish their course of therapy and have a follow-up HCV PCR at 12 weeks posttreatment, or whose recorded HCV status in their general practice record has yet to be updated to reflect treatment response.
Discussion
Limitations
We acknowledge that a key methodological constraint was our dependence on the data available through the MedicineInsight program. Previous studies found MedicineInsight data viable for estimating the prevalence of musculoskeletal disorders 5 and post-market drug surveillance. 6 Data availability in MedicineInsight depends on whether diagnoses, tests or assessments have been recorded in the patient's general practice record and whether they have been recorded in fields from which data can be extracted and analysed. For example, although there is limited access to fibrosis assessment in some settings, 7 the level of FibroScan testing found in the study was unexpectedly low; this is likely to reflect the recording of these tests in data fields not collected/extracted by MedicineInsight (eg in progress notes or as PDF attachments) or these assessments having been performed in tertiary care settings. In addition, MedicineInsight does not capture whether patients have declined offered treatment or reasons why a patient may decline testing or treatment when it has been offered. Given the lack of PCR results and resulting reliance on recorded diagnosis and indirect indications of CHC status, some patients may have been inaccurately assigned to one of the two study groups. A follow-up study would be useful to validate the study's findings with the full medical records of a sample of patients.
Despite these limitations, however, our results strongly indicate that there is a substantial opportunity for GPs to recall more patients with CHC for confirmation of diagnosis and pretreatment assessment. This can improve access to highly effective and well-tolerated DAA regimens for CHC, which are now also available for prescription in the primary care setting.
Implications for general practice
The majority of patients with CHC appear suitable for management of HCV in primary care. Proactive reviews of patient records by GPs to identify patients living with HCV infection are critical to maintain treatment momentum. anti-HBs = hepatitis B surface antibody. APRI = aspartate aminotransferase to platelet ratio index. MELD = Model for End-Stage Liver Disease. HCC = hepatocellular carcinoma. * As there are no safety data for the use of any direct-acting antiviral regimen during pregnancy, treatment of pregnant women is not recommended. Ribavirin (Category X) and peginterferon-alfa are contraindicated during pregnancy.
DAA, direct-acting antivirals; IFN, interferon
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